Evaluation of Efficacy and Safety of QLC7401 in Participants With Heterozygous Familial Hypercholesterolemia on a Stable Lipid-lowering Therapy: A Multicenter, Randomized, Double-blind, Placebo-controlled Phase III Clinical Study
Latest Information Update: 10 Mar 2026
At a glance
- Drugs RBD-7022 (Primary)
- Indications Hyperlipoproteinaemia type IIa
- Focus Registrational; Therapeutic Use
- Sponsors Qilu Pharmaceutical
Most Recent Events
- 10 Mar 2026 New trial record